{
  "id": "620bedb13a8413c653000004",
  "type": "summary",
  "question": "How do CYP1A2 polymorphisms affect the habitual coffee consumption effect on apetite?",
  "ideal_answer": "The CYP1A2 polymorphism -163C\u2009>\u2009A (rs762551) polymorphism renders carriers:  rapid (AA), intermediate (AC), or slow (CC) caffeine metabolizers.\nHigh coffee consumption was more prevalent in rapid compared to slow metabolizers (P\u2009=\u20090.008 after adjustment for age, sex, and BMI) and was associated with lower appetite perception and lower BMI only in rapid metabolizers (P for interaction of rs762551 genotype*coffee consumption\u2009=\u20090.002 and 0.048, respectively).",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/34564706"
  ],
  "snippets": [
    {
      "text": "CYP1A2 polymorphisms modify the association of habitual coffee consumption with appetite, macronutrient intake, and body mass index: results from an observational cohort and a cross-over randomized study.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34564706",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "CYP1A2 rs762551 polymorphism modifies the association of habitual coffee consumption with BMI, in part by influencing appetite, energy intake and circulating levels of the orexigenic hormone asprosin. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34564706",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Coffee consumption led to lower energy and dietary fat intake and circulating asprosin levels (P for interaction of rs762551 genotype*coffee consumption=0.056, 0.039, and 0.043, respectively) as compared to slow/intermediate metabolizers. High coffee consumption was more prevalent in rapid compared to slow metabolizers (P\u2009=\u20090.008 after adjustment for age, sex, and BMI) and was associated with lower appetite perception and lower BMI only in rapid metabolizers (P for interaction of rs762551 genotype*coffee consumption\u2009=\u20090.002 and 0.048, respectively). ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34564706",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Participants were stratified according to a validated genetic risk score (GRS) for obesity and to the -163C\u2009>\u2009A (rs762551) polymorphism of CYP1A2 as rapid (AA), intermediate (AC), or slow (CC) caffeine metabolizers",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34564706",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": []
}